{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:53:18Z","timestamp":1791312798328,"version":"4.3.1"},"reference-count":75,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2011,6,8]],"date-time":"2011-06-08T00:00:00Z","timestamp":1307491200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0020597","type":"journal-article","created":{"date-parts":[[2011,6,17]],"date-time":"2011-06-17T20:06:46Z","timestamp":1308341206000},"page":"e20597","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":44,"title":["Antibody against Extracellular Vaccinia Virus (EV) Protects Mice through Complement and Fc Receptors"],"prefix":"10.1371","volume":"6","author":[{"given":"Matthew E.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roselyn J.","family":"Eisenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary H.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart N.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,6,8]]},"reference":[{"key":"ref1","article-title":"Smallpox and its eradication.","author":"F Fenner","year":"1988"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0140-6736(06)68143-9","article-title":"Smallpox.","volume":"367","author":"ZS Moore","year":"2006","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/DDDT.S3687","article-title":"ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile.","volume":"4","author":"A Nalca","year":"2010","journal-title":"Drug Des Devel Ther"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1473-3099(01)00132-3","article-title":"USA to increase smallpox vaccine stockpile.","volume":"1","author":"J Bradbury","year":"2001","journal-title":"Lancet Infect Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1086\/375825","article-title":"Smallpox vaccination: a review, part II. Adverse events.","volume":"37","author":"VA Fulginiti","year":"2003","journal-title":"Clin Infect Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/j.vaccine.2005.01.012","article-title":"The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program.","volume":"23","author":"GA Poland","year":"2005","journal-title":"Vaccine"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1001\/archdermatol.2010.46","article-title":"Adverse events following smallpox vaccination with ACAM2000 in a military population.","volume":"146","author":"TM Beachkofsky","year":"2010","journal-title":"Arch Dermatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"824","DOI":"10.4161\/hv.10295","article-title":"Smallpox vaccines: New formulations and revised strategies for vaccination.","volume":"5","author":"N Paran","year":"2009","journal-title":"Hum Vaccin"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"D73","DOI":"10.1016\/j.vaccine.2009.07.103","article-title":"Smallpox vaccines for biodefense.","volume":"27","author":"RB Kennedy","year":"2009","journal-title":"Vaccine"},{"key":"ref10","first-page":"838","article-title":"Improved Smallpox Vaccines in New Generation Vaccines;","author":"ME Cohen","year":"2009"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/14760584.8.1.13","article-title":"IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine.","volume":"8","author":"JS Kennedy","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"ref12","article-title":"FDA Fast Track status for IMVAMUNE.","volume":"368 - 372","author":"EM Riedmann","year":"2010","journal-title":"Hum Vaccin 6:"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"9458","DOI":"10.1073\/pnas.1233578100","article-title":"Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.","volume":"100","author":"IM Belyakov","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nm1261","article-title":"Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus.","volume":"11","author":"Y Edghill-Smith","year":"2005","journal-title":"Nat Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/viro.1998.9516","article-title":"Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.","volume":"254","author":"MC Galmiche","year":"1999","journal-title":"Virology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/nm917","article-title":"Duration of antiviral immunity after smallpox vaccination.","volume":"9","author":"E Hammarlund","year":"2003","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.0105-2896.2006.00392.x","article-title":"Immunity and immunological memory following smallpox vaccination.","volume":"211","author":"IJ Amanna","year":"2006","journal-title":"Immunol Rev"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0065-3527(06)66002-8","article-title":"In a nutshell: structure and assembly of the vaccinia virion.","volume":"66","author":"RC Condit","year":"2006","journal-title":"Adv Virus Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1099\/0022-1317-50-1-89","article-title":"Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia.","volume":"50","author":"LG Payne","year":"1980","journal-title":"J Gen Virol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1099\/0022-1317-66-3-643","article-title":"Extracellular release of enveloped vaccinia virus from mouse nasal epithelial cells in vivo.","volume":"3)","author":"LG Payne","year":"1985","journal-title":"J Gen Virol 66 ( Pt"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1099\/0022-1317-83-12-2915","article-title":"The formation and function of extracellular enveloped vaccinia virus.","volume":"83","author":"GL Smith","year":"2002","journal-title":"J Gen Virol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.tim.2008.07.009","article-title":"Vaccinia virus morphogenesis and dissemination.","volume":"16","author":"KL Roberts","year":"2008","journal-title":"Trends Microbiol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1128\/JVI.78.19.10230-10237.2004","article-title":"Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.","volume":"78","author":"C Fogg","year":"2004","journal-title":"J Virol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/viro.1999.0096","article-title":"DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge.","volume":"266","author":"JW Hooper","year":"2000","journal-title":"Virology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1128\/JVI.78.9.4433-4443.2004","article-title":"Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox.","volume":"78","author":"JW Hooper","year":"2004","journal-title":"J Virol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1128\/JVI.79.21.13454-13462.2005","article-title":"Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge.","volume":"79","author":"S Lustig","year":"2005","journal-title":"J Virol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1006\/viro.1995.1378","article-title":"A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies.","volume":"211","author":"EJ Wolffe","year":"1995","journal-title":"Virology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.virol.2005.09.056","article-title":"Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host.","volume":"345","author":"M Fang","year":"2006","journal-title":"Virology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1073\/pnas.0510598103","article-title":"Chimpanzee\/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus.","volume":"103","author":"Z Chen","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"6864","DOI":"10.1073\/pnas.0701451104","article-title":"Smallpox subunit vaccine produced in Planta confers protection in mice.","volume":"104","author":"M Golovkin","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.virol.2004.07.024","article-title":"Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement.","volume":"328","author":"S Lustig","year":"2004","journal-title":"Virology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.vaccine.2006.10.009","article-title":"A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.","volume":"25","author":"Y Xiao","year":"2007","journal-title":"Vaccine"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1016\/j.vaccine.2006.12.037","article-title":"Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges.","volume":"25","author":"CN Fogg","year":"2007","journal-title":"Vaccine"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.1016\/j.vaccine.2010.07.030","article-title":"A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge.","volume":"28","author":"GW Buchman","year":"2010","journal-title":"Vaccine"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.4049\/jimmunol.177.4.2552","article-title":"Subunit recombinant vaccine protects against monkeypox.","volume":"177","author":"JM Heraud","year":"2006","journal-title":"J Immunol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1128\/JVI.02244-07","article-title":"Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine.","volume":"82","author":"MR Benhnia","year":"2008","journal-title":"J Virol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.vaccine.2009.09.086","article-title":"The smallpox vaccine induces an early neutralizing IgM response.","volume":"28","author":"JE Moyron-Quiroz","year":"2009","journal-title":"Vaccine"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1099\/0022-1317-78-8-2041","article-title":"Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation.","volume":"8)","author":"A Vanderplasschen","year":"1997","journal-title":"J Gen Virol 78 ( Pt"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.virol.2004.05.004","article-title":"Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin.","volume":"325","author":"E Bell","year":"2004","journal-title":"Virology"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1006\/viro.2000.0750","article-title":"Antibody neutralization of the extracellular enveloped form of vaccinia virus.","volume":"280","author":"M Law","year":"2001","journal-title":"Virology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.micinf.2005.02.004","article-title":"Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccinees.","volume":"7","author":"KM Viner","year":"2005","journal-title":"Microbes Infect"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"12355","DOI":"10.1128\/JVI.01593-09","article-title":"Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5.","volume":"83","author":"MR Benhnia","year":"2009","journal-title":"J Virol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1128\/JVI.01797-08","article-title":"Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement.","volume":"83","author":"MR Benhnia","year":"2009","journal-title":"J Virol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1128\/JVI.79.12.7466-7477.2005","article-title":"Complement activation is required for induction of a protective antibody response against West Nile virus infection.","volume":"79","author":"E Mehlhop","year":"2005","journal-title":"J Virol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1182\/blood-2009-01-200469","article-title":"Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model.","volume":"114","author":"SY Wang","year":"2009","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0022-1759(84)90045-0","article-title":"Cobra venom factor: improved method for purification and biochemical characterization.","volume":"73","author":"CW Vogel","year":"1984","journal-title":"J Immunol Methods"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.virol.2009.04.012","article-title":"Vaccinia virus strain differences in cell attachment and entry.","volume":"389","author":"Z Bengali","year":"2009","journal-title":"Virology"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1006\/viro.1994.1405","article-title":"Identification of a vaccinia virus penetration protein.","volume":"202","author":"Y Ichihashi","year":"1994","journal-title":"Virology"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"7544","DOI":"10.1073\/pnas.95.13.7544","article-title":"Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope.","volume":"95","author":"A Vanderplasschen","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref50","first-page":"1222","article-title":"Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and\/or decay-accelerating factor.","volume":"58","author":"B Charreau","year":"1994","journal-title":"Transplantation"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"15553","DOI":"10.1073\/pnas.95.26.15553","article-title":"CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice.","volume":"95","author":"CL Brazolot Millan","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.186.10.1623","article-title":"CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity.","volume":"186","author":"RS Chu","year":"1997","journal-title":"J Exp Med"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.4049\/jimmunol.160.8.3627","article-title":"CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis.","volume":"160","author":"S Zimmermann","year":"1998","journal-title":"J Immunol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1574-695X.2001.tb00535.x","article-title":"CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.","volume":"32","author":"RD Weeratna","year":"2001","journal-title":"FEMS Immunol Med Microbiol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1128\/JVI.79.10.6260-6271.2005","article-title":"Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R.","volume":"79","author":"L Aldaz-Carroll","year":"2005","journal-title":"J Virol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nri2620","article-title":"Complement regulators and inhibitory proteins.","volume":"9","author":"PF Zipfel","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"12708","DOI":"10.1073\/pnas.96.22.12708","article-title":"Humoral response to herpes simplex virus is complement-dependent.","volume":"96","author":"XJ Da Costa","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4049\/jimmunol.170.1.84","article-title":"Impaired antibody response to group B streptococcal type III capsular polysaccharide in C3- and complement receptor 2-deficient mice.","volume":"170","author":"O Pozdnyakova","year":"2003","journal-title":"J Immunol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1084\/jem.190.8.1165","article-title":"Protective T cell-independent antiviral antibody responses are dependent on complement.","volume":"190","author":"AF Ochsenbein","year":"1999","journal-title":"J Exp Med"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/icb.2009.110","article-title":"Antiviral protection following immunization correlates with humoral but not cell-mediated immunity.","volume":"88","author":"V Panchanathan","year":"2010","journal-title":"Immunol Cell Biol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"12921","DOI":"10.1073\/pnas.0505180102","article-title":"Interferon function is not required for recovery from a secondary poxvirus infection.","volume":"102","author":"V Panchanathan","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1128\/JVI.00115-06","article-title":"Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function.","volume":"80","author":"V Panchanathan","year":"2006","journal-title":"J Virol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1084\/jem.20012024","article-title":"Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody.","volume":"195","author":"S Azeredo da Silveira","year":"2002","journal-title":"J Exp Med"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/0161-5890(80)90139-X","article-title":"Isotypes of mouse IgG--I. Evidence for \u2018non-complement-fixing\u2019 IgG1 antibodies and characterization of their capacity to interfere with IgG2 sensitization of target red blood cells for lysis by complement.","volume":"17","author":"PL Ey","year":"1980","journal-title":"Mol Immunol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/eji.1830111212","article-title":"Activation of mouse complement by monoclonal mouse antibodies.","volume":"11","author":"MS Neuberger","year":"1981","journal-title":"Eur J Immunol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1126\/science.1118948","article-title":"Divergent immunoglobulin g subclass activity through selective Fc receptor binding.","volume":"310","author":"F Nimmerjahn","year":"2005","journal-title":"Science"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.coi.2008.06.012","article-title":"Molecular engineering and design of therapeutic antibodies.","volume":"20","author":"LG Presta","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature06106","article-title":"Fc receptor but not complement binding is important in antibody protection against HIV.","volume":"449","author":"AJ Hessell","year":"2007","journal-title":"Nature"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1089\/vim.2009.0107","article-title":"A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice.","volume":"23","author":"KN Delaney","year":"2010","journal-title":"Viral Immunol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1126\/science.1373518","article-title":"CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes.","volume":"256","author":"RH Carter","year":"1992","journal-title":"Science"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1126\/science.280.5363.582","article-title":"Dependence of germinal center B cells on expression of CD21\/CD35 for survival.","volume":"280","author":"MB Fischer","year":"1998","journal-title":"Science"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.addr.2008.12.012","article-title":"CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases.","volume":"61","author":"DM Klinman","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/08830180600743057","article-title":"Adjuvant activity of CpG oligodeoxynucleotides.","volume":"25","author":"DM Klinman","year":"2006","journal-title":"Int Rev Immunol"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/BF00395856","article-title":"The mouse Igh-1a and Igh-1b H chain constant regions are derived from two distinct isotypic genes.","volume":"29","author":"E Jouvin-Marche","year":"1989","journal-title":"Immunogenetics"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0022-1759(98)00015-5","article-title":"The need for IgG2c specific antiserum when isotyping antibodies from C57BL\/6 and NOD mice.","volume":"212","author":"RM Martin","year":"1998","journal-title":"J Immunol Methods"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0020597","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T12:37:19Z","timestamp":1686141439000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0020597"}},"subtitle":[],"editor":[{"given":"Ralph","family":"Tripp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,6,8]]},"references-count":75,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2011,6,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0020597","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,8]]}}}